{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:00:14Z","timestamp":1793314814537,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Concerns exist about teratogenic and long-term neurodevelopmental outcomes of paternal use of valproate during spermatogenesis.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association between paternal use of valproate during spermatogenesis and offspring risk of congenital malformations and neurodevelopmental disorders.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nationwide cohort study included 1\u202f235\u202f353 singletons born in Denmark between January 1, 1997, and December 31, 2017, identified in the Medical Birth Register; 1336 children had fathers who had filled prescriptions for valproate during spermatogenesis. Congenital malformations were identified in the first year of life and neurodevelopmental disorders were identified from 1 year of age until December 31, 2018. Statistical analysis was performed March 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Paternal valproate exposure was defined as fathers who filled 1 or more prescriptions for valproate immediately before or during the time of spermatogenesis (ie, 3 months prior to conception).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Children with major congenital malformations in the first year of life and with neurodevelopmental disorders before death or end of follow-up were identified in Danish health registers. Log-binomial regression was used to estimate adjusted relative risks (ARRs) of congenital malformations, and Cox proportional hazards regression was used to estimate adjusted hazards ratios (AHRs) of neurodevelopmental disorders, adjusted for relevant confounders.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 1\u202f235\u202f353 live births (634\u202f415 boys [51.4%] and 600\u202f938 girls [48.6%]), 1336 children (0.1%) had fathers who filled prescriptions for valproate during spermatogenesis. The median follow-up was 10.1 years (IQR, 5.1-14.8 years) for valproate-exposed children and 10.3 years (IQR, 5.2-15.6 years) for valproate-unexposed children. A total of 43\u202f903 children (3.6%) received a diagnosis of major congenital malformations in the first year of life, and 51\u202f633 children (4.2%) received a diagnosis of neurodevelopmental disorders during follow-up. When comparing the risk among valproate-exposed children with that among unexposed children, the ARR of major congenital malformations was 0.89 (95% CI, 0.67-1.18), the AHR of neurodevelopmental disorders was 1.10 (95% CI, 0.88-1.37), and the AHR of autism spectrum disorder was 0.92 (95% CI, 0.65-1.30). In analyses addressing the robustness of the findings (ie, dose-response analyses, sibling analyses, analyses restricted to children of fathers with epilepsy, analyses that used children with paternal lamotrigine exposure as active comparator, and analyses that used children with paternal exposure to valproate only before spermatogenesis as a negative control exposure), there still was no increased risk of any of the included end points.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In all analyses based on this large Danish cohort study, results suggest that exposure to valproate during spermatogenesis was not associated with offspring risk of congenital malformations or neurodevelopmental disorders, including autism spectrum disorder.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.14709","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:36:35Z","timestamp":1717508195000},"page":"e2414709","source":"Crossref","is-referenced-by-count":50,"title":["Valproate Use During Spermatogenesis and Risk to Offspring"],"prefix":"10.1001","volume":"7","author":[{"given":"Jakob","family":"Christensen","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, Aarhus, Denmark"},{"name":"Department of Neurology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina B.","family":"Trabjerg","sequence":"additional","affiliation":[{"name":"National Centre for Register-based Research, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark"},{"name":"Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie Werenberg","family":"Dreier","sequence":"additional","affiliation":[{"name":"National Centre for Register-based Research, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark"},{"name":"Centre for Integrated Register-based Research, Aarhus University, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"issue":"1","key":"zoi240500r1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eplepsyres.2007.06.012","article-title":"Incidence and prevalence of epilepsy in Denmark.","volume":"76","author":"Christensen","year":"2007","journal-title":"Epilepsy Res"},{"key":"zoi240500r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.06.010","article-title":"Estimates of epilepsy prevalence, psychiatric co-morbidity and cost.","volume":"107","author":"Christensen","year":"2023","journal-title":"Seizure"},{"issue":"11","key":"zoi240500r3","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1111\/epi.v62.11","article-title":"Exploring the prevalence and profile of epilepsy across Europe using a standard retrospective chart review: challenges and opportunities.","volume":"62","author":"Linehan","year":"2021","journal-title":"Epilepsia"},{"issue":"9566","key":"zoi240500r4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"issue":"10282","key":"zoi240500r5","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"zoi240500r6","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1111\/epi.v62.12","article-title":"Prenatal exposure to valproate and risk of congenital malformations\u2014could we have known earlier?\u2014a population-based cohort study.","volume":"62","author":"Christensen","year":"2021","journal-title":"Epilepsia"},{"issue":"8","key":"zoi240500r7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.","volume":"8","author":"Bromley","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"zoi240500r8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability.","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"16","key":"zoi240500r9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi240500r14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10654-018-0356-1","article-title":"The Danish Medical Birth Register.","volume":"33","author":"Bliddal","year":"2018","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"zoi240500r15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System.","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"issue":"7","key":"zoi240500r16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry.","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"issue":"7","key":"zoi240500r17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register.","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"zoi240500r18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential.","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"2","key":"zoi240500r20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamapsychiatry.2019.3523","article-title":"Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence.","volume":"77","author":"Dalsgaard","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi240500r21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1403494810395825","article-title":"The Danish Psychiatric Central Research Register.","volume":"39","author":"Mors","year":"2011","journal-title":"Scand J Public Health"},{"issue":"7","key":"zoi240500r22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1403494811399958","article-title":"The Danish Register of Causes of Death.","volume":"39","author":"Helweg-Larsen","year":"2011","journal-title":"Scand J Public Health"},{"key":"zoi240500r23","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2147\/CLEP.S278596","article-title":"Congenital malformations in Denmark: considerations for the use of Danish health care registries.","volume":"12","author":"Broe","year":"2020","journal-title":"Clin Epidemiol"},{"key":"zoi240500r25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1403494810394715","article-title":"Danish education registers.","volume":"39","author":"Jensen","year":"2011","journal-title":"Scand J Public Health"},{"issue":"3","key":"zoi240500r26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies.","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"4","key":"zoi240500r27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.2019.20008","article-title":"First-trimester pregnancy exposure to modafinil and risk of congenital malformations.","volume":"323","author":"Damkier","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"zoi240500r28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007425","article-title":"Apgar-score in children prenatally exposed to antiepileptic drugs: a population-based cohort study.","volume":"5","author":"Christensen","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"zoi240500r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.6606","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit\/hyperactivity disorder in offspring.","volume":"2","author":"Christensen","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi240500r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.25570","article-title":"Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones.","volume":"3","author":"Daugaard","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi240500r31","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/jnnp-2020-323028","article-title":"Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden.","volume":"91","author":"Tomson","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"zoi240500r32","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/epi.2013.54.issue-8","article-title":"Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.","volume":"54","author":"Veiby","year":"2013","journal-title":"Epilepsia"},{"issue":"7","key":"zoi240500r33","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/pds.v28.7","article-title":"Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.","volume":"28","author":"Huybrechts","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"17","key":"zoi240500r34","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1001\/jama.2018.11328","article-title":"Cumulative incidence of autism into adulthood for birth cohorts in Denmark, 1980-2012.","volume":"320","author":"Schendel","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"zoi240500r35","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1212\/WNL.0000000000007696","article-title":"Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs.","volume":"93","author":"Bloti\u00e8re","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"zoi240500r36","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"zoi240500r37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10803-009-0818-0","article-title":"Validity of childhood autism in the Danish Psychiatric Central Register: findings from a cohort sample born 1990-1999.","volume":"40","author":"Lauritsen","year":"2010","journal-title":"J Autism Dev Disord"},{"key":"zoi240500r19","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"zoi240500r10","unstructured":"UK Medicines and Healthcare Products Regulatory Agency. Valproate: review of safety data and expert advice on management of risks. 2023. Accessed April 17, 2024. https:\/\/www.gov.uk\/government\/publications\/valproate-review-of-safety-data-and-expert-advice-on-management-of-risks"},{"key":"zoi240500r11","unstructured":"European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). Procedure under Article 31 of Directive 2001\/83\/EC resulting from pharmacovigilance data: substances related to valproate. Procedure number: EMEA\/H\/A-31\/1387. Accessed November 18, 2023. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/valproate-related-substances-article-31-referral-prac-assessment-report_en.pdf"},{"key":"zoi240500r12","unstructured":"European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). EMA review of data on paternal exposure to valproate. Updated August 16, 2023. Accessed April 17, 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-review-data-paternal-exposure-valproate"},{"key":"zoi240500r13","unstructured":"European Medicines Agency, Pharmacovigilance Risk Assessment Committee (PRAC). PRAC non-interventional imposed PASS final study report assessment report. 2024. Accessed April 17, 2024. https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/emea-h-n-psr-j-0043-epar_en.pdf"},{"key":"zoi240500r24","unstructured":"European Surveillance of Congenital Anomalies. EUROCAT Guide 1.4: instruction for the registration of congenital anomalies. EUROCAT Central Registry, University of Ulster. 2013. Accessed April 17, 2024. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2819450\/christensen_2024_oi_240500_1716576011.4231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T13:36:41Z","timestamp":1717508201000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2819450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.14709","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]}}}